Alerta

Century Therapeutics Inc. (IPSC)

NasdaqCM: IPSC · Precio en tiempo real · USD

1.96

-0.10 (-4.85%)

Al cierre: Aug 12, 2026, 3:59 PM

-4.85% (1D)

Precio de compra	1.47
Capitalización de mercado	354.91M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-109.79M
Beta	1.60
EPS (TTM)	-0.93
Ratio PER (TTM)	n/a
Adelante PE	-4.28
P/B (TTM)	1.33
P/S (TTM)	n/a
Earnings Date	Nov 12, 2026

Precio de venta	2.54
Volumen	514,956
Volumen medio (20D)	1,254,522
Abierto	2.08
Anterior Cerrar	2.06
Rango del día	1.96 - 2.09
Rango de 52 semanas	0.43 - 3.04
analista	n/a
Precio objetivo	4.5 (129.59%)
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de IPSC

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jun 18, 2021

Empleados 78

Bolsa de Valores NasdaqCM

Símbolo bursátil IPSC

Sitio web https://www.centurytx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Century Therapeutics fueron 109.16M, un aumento de 1,556.76% en comparación con 6.59M del año anterior. Las ganancias fueron -9.58M, una disminución de -92.43%.

Estados financieros

Pronóstico del analista

Según las calificaciones de los analistas de 4, la calificación promedio de las acciones de IPSC es "null". El pronóstico del precio de las acciones a 12 meses es 4.5, que es Potencial alcista de 129.59% del último precio.

Previsiones bursátiles

Sorpresa de resultados

Nuevo

Century Therapeutics ha publicado sus resultados trimestrales en Aug 12, 2026:

Ingresos de $0 falla las estimaciones por $0, con -100.00% Disminución interanual.

EPS de -0.11 supera las estimaciones en 0.01, con 71.05% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Century Therapeutics Inc. publique sus resultados el Nov 12, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

4 semanas hace · Insider Monkey

Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses

Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 9, 2026, Century Therapeutics, Inc. (NASDAQ:IPSC) announced that its abstracts were accepted...

2 meses hace · Simply Wall St.

Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

2 meses hace · Insider Monkey

Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813

Century Therapeutics, Inc. (NASDAQ:IPSC), featuring a year-to-date gain of 114.11% and upside potential of 134.70%, secures a spot on our list of hot biotech stocks under $5 to buy. New preclinical da...

3 meses hace · Insider Monkey

H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)

Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the best performing small cap stocks so far in 2026. H.C. Wainwright lifted the price target on Century Therapeutics, Inc. (NASDAQ:IPSC) to $5 from $...

6 meses hace · Insider Monkey

Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission

Century Therapeutics Inc. (NASDAQ:IPSC) is one of the best fast growing penny stocks to buy according to analysts. On January 20, Piper Sandler increased its price target for Century Therapeutics to $...

Página 1 de 2

Century Therapeutics Inc. (IPSC)